Table 1: Melanoma: Key Metrics in Seven Major Pharmaceutical Markets
Table 2: Pathologic Stage Definitions for Melanoma
Table 3: The ABCED Rule of Melanoma Detection
Table 4: Prognosis of Melanoma
Table 5: Risk Factors for Melanoma
Table 6: 7MM, Diagnosed Incident Cases of Melanoma, Men and Women, Ages ≥18 Years, Select Years 2016–2026
Table 7: 7MM, Five-Year Diagnosed Prevalent Cases of Melanoma, Men and Women, Ages ≥18 Years, Select Years 2016–2026
Table 8: Clinical Guidelines for Melanoma
Table 9: Most Prescribed Drugs for Melanoma in the Global Markets by Class, 2016
Table 10: Country Profile – US
Table 11: Country Profile – France
Table 12: Country Profile – Germany
Table 13: Country Profile – Italy
Table 14: Country Profile – Spain
Table 15: Country Profile – UK
Table 16: Country Profile – Australia
Table 17: Leading Treatments for Melanoma, 2016
Table 18: Product Profile – Roferon-A
Table 19: Efficacy of Roferon-A
Table 20: Safety of Roferon-A
Table 21: Roferon-A SWOT Analysis, 2016
Table 22: Product Profile – Intron A
Table 23: Efficacy of Intron A from the Phase III E1684 Trial
Table 24: Safety of Intron A (E1684, E1690, and E1694)
Table 25: Intron A SWOT Analysis, 2015
Table 26: Product Profile – Sylatron
Table 27: Efficacy of Sylatron from the EORTC 18991 Trial
Table 28: Head-to-Head Comparison Between Sylatron and Low-Dose Interferon
Table 29: Safety of Sylatron from the EORTC 18991 Trial
Table 30: Sylatron SWOT Analysis, 2015
Table 31: Product Profile – Yervoy
Table 32: Yervoy Key Regulatory and Reimbursement Milestones in the US Melanoma Market
Table 33: Yervoy Key Regulatory and Reimbursement Milestones in the EU Melanoma Market
Table 34: Yervoy Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market
Table 35: Efficacy of Yervoy from the Phase III CA184-002 Trial
Table 36: Comparison of Higher Dose Yervoy and DTIC from the CA184-024 Trial
Table 37: Network Meta-analysis of Yervoy in the Advanced Setting
Table 38: Efficacy Data Comparing Yervoy 3mg/kg to Yervoy 10mg/kg from the CA184-169 Trial
Table 39: Efficacy of Yervoy in the Adjuvant Melanoma Setting from the CA184-029 Trial
Table 40: Safety of Yervoy at 3mg/kg in the Advanced Melanoma Setting from the CA184-002 trial
Table 41: Safety Data Comparing Yervoy 3mg/kg to Yervoy 10mg/kg from the CA184-169 Trial
Table 42: Safety of Yervoy in the Adjuvant Setting from the CA184-029 Trial
Table 43: Yervoy SWOT Analysis, 2017
Table 44: Product Profile – Opdivo
Table 45: Opdivo’s Key Regulatory and Reimbursement Milestones in the US Melanoma Market
Table 46: Opdivo’s Key Regulatory and Reimbursement Milestones in the EU Melanoma Market
Table 47: Opdivo’s Key Regulatory Milestones in the Australian Melanoma Market
Table 48: Efficacy of Opdivo in 1L BRAF-WT Advanced Melanoma from the CheckMate 066 Trial
Table 49: Efficacy of Opdivo + Yervoy from the CheckMate 067 Trial
Table 50: Safety Data from the CheckMate 037 Trial
Table 51: Safety Data from the CheckMate 066 Trial
Table 52: Safety Data from the CheckMate 067 Trial
Table 53: Opdivo SWOT Analysis, 2017
Table 54: Product Profile – Keytruda
Table 55: Keytruda Key Regulatory and Reimbursement Milestones in the US Melanoma Market
Table 56: Keytruda Key Regulatory and Reimbursement Milestones in the EU Melanoma Market
Table 57: Keytruda Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market
Table 58: Survival Data from the Phase Ib KEYNOTE-001 Trial
Table 59: Efficacy of Keytruda from the KEYNOTE-002 Trial
Table 60: Efficacy of Keytruda from the KEYNOTE-006 Trial
Table 61: Efficacy of Keytruda in Combinations in the 1L Setting
Table 62: Safety Data from the KEYNOTE-001 Trial
Table 63: Safety of Keytruda from the KEYNOTE-002 Trial
Table 64: Safety Data from the KEYNOTE-006 Trial
Table 65: Safety of Keytruda in the 1L Setting from 2016 ASCO Annual Meeting
Table 66: Keytruda SWOT Analysis, 2017
Table 67: Product Profile – Zelboraf
Table 68: Zelboraf’s Key Regulatory and Reimbursement Milestones in the US Melanoma Market
Table 69: Zelboraf’s Key Regulatory and Reimbursement Milestones in the EU Melanoma Market
Table 70: Zelboraf’s Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market
Table 71: Efficacy of Zelboraf
Table 72: Safety of Zelboraf
Table 73: Zelboraf SWOT Analysis, 2017
Table 74: Product Profile – Cotellic
Table 75: Cotellic’s Key Regulatory and Reimbursement Milestones in the US Melanoma Market
Table 76: Cotellic’s Key Regulatory and Reimbursement Milestones in the EU Melanoma Market
Table 77: Cotellic’s Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market
Table 78: Efficacy of Cotellic in BRAF V600 Mutation-Positive Advanced Melanoma from the coBRIM Trial
Table 79: Safety Data of Cotellic from the coBRIM Trial
Table 80: Cotellic SWOT Analysis, 2017
Table 81: Product Profile – Tafinlar
Table 82: Tafinlar’s Key Regulatory and Reimbursement Milestones in the US Melanoma Market
Table 83: Tafinlar’s Key Regulatory and Reimbursement Milestones in the EU Melanoma Market
Table 84: Tafinlar’s Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market
Table 85: Efficacy of Tafinlar Monotherapy from the BREAK-3 Trial
Table 86: Safety of Tafinlar
Table 87: Tafinlar SWOT Analysis, 2017
Table 88: Product Profile – Mekinist
Table 89: Mekinist’s Key Regulatory and Reimbursement Milestones in the US Melanoma Market
Table 90: Mekinist’s Key Regulatory and Reimbursement Milestones in the EU Melanoma Market
Table 91: Mekinist’s Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market
Table 92: Efficacy of Mekinist from the Phase III METRIC Trial
Table 93: Efficacy Results of Tafinlar + Mekinist from the Phase II NCT01072175 Trial
Table 94: Efficacy Results of the COMBI-d Trial
Table 95: Efficacy Results of Tafinlar + Mekinist from the COMBI-v Trial
Table 96: Safety of Mekinist from the Phase III METRIC Trial
Table 97: Safety Results of the COMBI-d Trial
Table 98: Safety Results of the COMBI-v Trial
Table 99: Mekinist SWOT Analysis, 2017
Table 100: Product Profile – Imlygic
Table 101: Imlygic’s Key Regulatory and Reimbursement Milestones in the US Melanoma Market
Table 102: Imlygic’s Key Regulatory and Reimbursement Milestones in the EU Melanoma Market
Table 103: Imlygic’s Key Regulatory and Reimbursement Milestones in the Australian Melanoma Market
Table 104: Efficacy of Imlygic from the Phase III OPTiM Trial
Table 105: Exploratory Subgroup Analyses from the Phase III OPTiM Trial
Table 106: Safety of Imlygic from the Phase III OPTiM Trial
Table 107: Imlygic SWOT Analysis, 2017
Table 108: Summary of Minor Therapeutic Classes, 2017
Table 109: Product Profile – Epacadostat
Table 110: Efficacy of Keytruda + Epacadostat from the Phase I/II KEYNOTE-037/ECHO-202 Trial
Table 111: Safety Data of Keytruda + Epacadostat from the Phase I/II KEYNOTE-037/ECHO-202 Trial
Table 112: Epacadostat SWOT Analysis, 2017
Table 113: Product Profile – Tecentriq
Table 114: Tecentriq SWOT Analysis, 2017
Table 115: Product Profile – PDR-001
Table 116: PDR-001 SWOT Analysis, 2017
Table 117: Product Profile – Encorafenib
Table 118: Efficacy of Encorafenib from the Phase III COLUMBUS Trial
Table 119: Safety of Encorafenib Regimens from the Phase III COLUMBUS Trial
Table 120: Encorafenib SWOT Analysis, 2017
Table 121: Product Profile – Binimetinib
Table 122: Efficacy of Binimetinib from the Phase III NEMO Trial
Table 123: Safety of Binimetinib from the Phase III NEMO Trial
Table 124: Binimetinib SWOT Analysis, 2017
Table 125: Product Profile – Masitinib
Table 126: Masitinib SWOT Analysis, 2017
Table 127: Product Profile – Seviprotimut-L
Table 128: Efficacy of Seviprotimut-L from the Phase II POL 89-38 Trial
Table 129: Seviprotimut-L SWOT Analysis, 2017
Table 130: Product Profile – PV-10
Table 131: Efficacy of PV-10 from the PV-10-MM-02 Trial
Table 132: Safety of PV-10
Table 133: PV-10 SWOT Analysis, 2017
Table 134: Product Profile – M-Vax
Table 135: Efficacy of M-Vax from the Phase I/II NCT00257465 Trial
Table 136: M-Vax SWOT Analysis, 2017
Table 137: Product Profile – Daromun (L19-IL2 + L19-TNF)
Table 138: Efficacy of Daromun from the Phase II NCT02076633 Trial
Table 139: Daromun SWOT Analysis, 2017
Table 140: Clinical Settings of Early-Stage Immunotherapies
Table 141: Clinical Settings of Early-Stage Next-Generation BRAF Inhibitors
Table 142: Clinical Settings of Early-Stage Drugs Targeting the PI3K/Akt/mTOR Pathway
Table 143: Clinical Settings of Early-Stage Drugs Targeting Cell Cycle Checkpoints
Table 144: Clinical Settings of Early-Stage Oncolytic Viral, Adoptive T-cell and Immunostimulants
Table 145: Drugs in Development, 2017
Table 146: Key Companies in the Melanoma Market in the 7MM, 2017
Table 147: BMS’ Melanoma Portfolio Assessment, 2017
Table 148: Novartis’ Melanoma Portfolio Assessment, 2017
Table 149: Merck & Co’s Melanoma Portfolio Assessment, 2017
Table 150: Roche’s Melanoma Portfolio Assessment, 2017
Table 151: Incyte’s Melanoma Portfolio Assessment, 2017
Table 152: Melanoma Market in the 7MM – Drivers, 2016–2026
Table 153: Melanoma Market in the 7MM – Barriers, 2016
Table 154: Key Events Impacting Sales for Melanoma in the US, 2016–2026
Table 155: Melanoma Market in the US – Drivers and Barriers, 2016–2026
Table 156: Key Events Impacting Sales for Melanoma in the 5EU, 2016–2026
Table 157: Melanoma Market in the 5EU – Drivers and Barriers, 2016–2026
Table 158: Melanoma Market in the 5EU – Country-Specific Drivers, 2016–2026
Table 159: Melanoma Market in the 5EU – Country-Specific Barriers, 2016–2026
Table 160: Key Events Impacting Sales for Melanoma in Australia, 2016–2026
Table 161: Melanoma Market in Australia – Drivers and Barriers, 2016–2026
Table 162: Key Launch Dates
Table 163: Key Patent Expiries
Table 164 Average Body Weight and Surface Area Across the 7MM
Table 165: High-Prescribing Physicians Surveyed by Country